MétaCan
Menu
Back to cohort

S2558 Primary Biliary Cholangitis: Second-Line Treatment and Outcomes at a Safety Net vs Tertiary Care Hospital Systems

2025· article· en· W4417239026 on OpenAlexaboutno aff
Meena M. Tadros, Prajwal Gowda, Maryln J. Mayo, Mark Pedersen, Saiabhiroop R. Govindu

Bibliographic record

VenueThe American Journal of Gastroenterology · 2025
Typearticle
Languageen
FieldMedicine
TopicLiver Diseases and Immunity
Canadian institutionsnot available
Fundersnot available
KeywordsUrsodeoxycholic acidMedicaidRetrospective cohort studyPrimary biliary cirrhosisCohortLiver diseaseBiliary diseaseAlkaline phosphataseCirrhosis

Abstract

fetched live from OpenAlex

Introduction: Primary Biliary Cholangitis (PBC) affects women of all racial and economic backgrounds and can lead to progressive liver damage and hepatic decompensation. Limited data exist regarding healthcare disparities and second-line therapy use in safety-net settings. We aimed to compare stages at diagnosis, biochemical responses, second-line therapy initiation rates, and clinical outcomes between patients at a safety-net hospital (SNH) and a tertiary care hospital (TCH) system. Methods: We conducted a retrospective cohort study reviewing 240 adult patients diagnosed with PBC from 2015-2024 at a SNH (n = 120) and a TCH (n = 120) in Dallas, Texas. Data included demographics, laboratory values (alkaline phosphatase, bilirubin, albumin), insurance status, and therapy utilization. Outcomes measured were UDCA biochemical response rates, second-line therapy initiation, and hepatic complications. Statistical analyses included chi-square for categorical variables and T-test for continuous variables. Results: Patients at the SNH were of similar age to those at TCH (53.0 vs 54.6 years) but had significantly higher rates of uninsured or Medicaid status (63% vs 8.3%; P < 0.001), were predominantly Hispanic (78.7% vs 15.0%, P < 0.001) and had AMA-negative disease diagnosed by biopsy more frequently (32.7% vs 4.2% < 0.001). These patients were more likely to receive ursodeoxycholic acid (99.1% vs 94.1%, P = 0.04), but also had a higher rate of cirrhosis at diagnosis (26.9% vs 7.5%, P < 0.0009), higher alkaline phosphatase (280 vs 206 IU/L, P = 0.03) and lower albumin (3.7 vs 4.2 mg/dL, P < 0.001) at 1 year. 72.2% of patients at the SNH met Toronto criteria based on alkaline phosphatase at 1 year after baseline visit. Patients at the TCH who met criteria for second line therapy were more likely to receive second line therapy with obeticholic acid or fenofibrate (14/19 vs 10/40, P = 0.02). However, when excluding the patients who had already decompensated the difference was not significant (82% vs 50%). Patients not receiving second-line therapy had trend toward increased hepatic decompensation (37.8% vs 30.8%). Conclusion: Significant disparities in PBC management exist between SNH and TCH highlighted by more severe disease, with lower biochemical response rates, and increased financial barriers. In spite of these challenges, access to ursodeoxycholic acid and second line therapies is similar between the hospital systems.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.017
Threshold uncertainty score0.033

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0010.002
Science and technology studies0.0010.000
Scholarly communication0.0010.001
Open science0.0000.001
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0060.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.004
GPT teacher head0.238
Teacher spread0.233 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueThe American Journal of GastroenterologySame topicLiver Diseases and ImmunityFrench-language works237,207